Tumor markers in aggressive b-cell lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how certain markers in your tumor sample might predict how your lymphoma will behave. It aims to see if these markers can help guide treatment decisions, so your care can be more personalized.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of fast-growing B-cell lymphoma called DLBCL or another aggressive B-cell lymphoma.
- A tissue sample (biopsy) was taken from your tumor before starting any lymphoma treatment.
- The biopsy sample is still available and of good enough quality for special lab tests.
- Your basic medical information (like age, sex, diagnosis date, and treatment status) is available.
- You have some follow-up information, like check-up dates or survival status, to allow the study to look at outcomes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood tests to find markers of inflammation in people newly diagnosed with B-cell blood cancers (such as certain lymphomas, leukemias, and multiple myeloma). It may help doctors better understand these diseases and how they affect the body.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This study looks at certain markers on your blood cancer cells to understand them better. By joining, you help doctors learn more about your disease, which may guide future care.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.